Saturday, November 2, 2024

BD Onclarity HPV Assay Approved in Canada for Self-Collected HPV Testing

Similar articles

Subscribe Weekly Market Access News

* indicates required

Key Takeaways

  • BD’s new self-collected HPV test brings accessible cervical cancer screening to women across Canada.
  • The assay supports accurate, at-home HPV testing with extended genotyping capabilities.
  • This advancement targets Canada’s goal of reducing cervical cancer rates and improving women’s health access.

BD (Becton, Dickinson and Company) has achieved a milestone in women’s health with Health Canada’s approval of the BD Onclarity HPV Assay, now enabling women in Canada to collect their own samples for HPV detection at home. This shift from traditional, clinician-administered Pap tests to self-collection offers greater accessibility for women in remote or underserved communities, expanding the reach of cervical cancer screening.

Self-collected HPV testing offers key benefits over traditional methods, such as reducing the need for invasive procedures, lowering costs, and extending the testing interval to five years, while maintaining the same diagnostic accuracy. This innovation minimizes barriers like travel or discomfort, providing women greater autonomy over their health. With BD’s initiative, healthcare access is enhanced, supporting proactive health management among Canadian women.

HPV

Advancing Canada’s Cervical Cancer Prevention Goals

HPV, the leading cause of cervical cancer, affects millions, with around 70% of cervical cancers in Canada linked to the virus. The Canadian Partnership Against Cancer has advocated for primary HPV screening to replace Pap tests, a vision supported by BD’s advancement. With 16.3 million Canadian women at risk, the BD Onclarity HPV Assay is uniquely positioned as the only Health Canada-approved test for self-collection with extended genotyping, improving risk assessments for cervical pre-cancer and cancer.

BD’s commitment to women’s health aligns with Canada’s goal to eliminate cervical cancer by 2040, and with this approved assay, women across the country can now access convenient and precise HPV screening from home, contributing to a future with lower cervical cancer rates.

 

Source: Becton, Dickinson and Company,October, 2024


This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article